Scholar Rock Unveils Remarkable SRK-439 Findings: Preserving Lean Mass, Curbing Fat Gain
Scholar Rock, a biotechnology company, has initiated the Phase 2 EMBRAZE trial to evaluate apitegromab, a myostatin inhibitor, for...
Scholar Rock, a biotechnology company, has initiated the Phase 2 EMBRAZE trial to evaluate apitegromab, a myostatin inhibitor, for...
Institute for Systems Biology (ISB) researchers have developed a new method to predict individual-specific short-chain fatty acid (SCFA) production...
Tectonic Therapeutic, Inc. (TECX) has merged with AVROBIO, Inc. and will operate as Tectonic Therapeutic, Inc., trading on Nasdaq...
The U.S. Food and Drug Administration (FDA) has granted traditional approval to ELEVIDYS for ambulatory Duchenne muscular dystrophyDuchenne muscular...
A phase 3 clinical trial known as PURPOSE 1 has yielded breakthrough results in HIV prevention. The trial studied...
CellxLife, a newly established company, aims to revolutionize treatment for children with recurring metastatic Ewing sarcoma and osteosarcoma. The...
Precision BioSciences, a gene editing company, has appointed Dr. Mark Sulkowski and Dr. Jordan Feld to its Hepatitis Scientific...
Bristol Myers Squibb has announced that the European Medicines Agency (EMA) has accepted an extension application for a new...
The FDA has approved KRAZATI (adagrasib) in combination with cetuximab as a treatment for locally advanced or metastatic colorectal...
AriBio Co., Ltd. has partnered with Kentucky Clinical Trial Laboratory (KCTL) to enhance Alzheimer’s diseaseAlzheimer’s disease testing. This collaboration...